Research programme: PET/CT imaging agents - J-PharmaAlternative Names: JPH-223
Latest Information Update: 21 Sep 2016
At a glance
- Originator J-Pharma
- Class Imaging agents
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 19 Sep 2016 Preclinical trials in Undefined indication in Japan (unspecified route)